Tirzepatide may be considered when a patient wants a medication with strong average weight-loss results and is medically appropriate for treatment
Using a large multicenter real-world dataset, we assessed clinical pregnancy, live birth, and time-to-event outcomes across body mass index subgroups to inform the reproductive safety profile of semaglutide and guide preconception counseling
For non-diabetic individuals struggling with obesity, these medications can support significant weight loss , with clinical trials showing an average reduction of 10-15% of body weight while also improving metabolic health and blood sugar regulation
Conditioning inclusion on documented weight loss may also introduce collider bias if women who successfully lost weight differ systematically in motivation, adherence, or metabolic responsiveness
This section would outline the current gaps in research and propose future directions to enhance our understanding of how semaglutide can be utilized effectively and safely for individuals facing fertility challenges
